All PlansAdministrativeMedium impact
Recall: Anagrelide
UPMC Health Plan·Hematology, Oncology, Internal Medicine·Pharmacy
We identified it
Jun 20, 2026
Summary
Teva has recalled one lot of Anagrelide 0.5 mg capsules due to slower than expected dissolution rates. This drug recall affects patients with high platelet count conditions and may require medication switches or alternative treatments.
Action Required
Immediately: Clinical staff should identify patients currently prescribed Anagrelide 0.5 mg capsules from the recalled lot. Contact affected patients and prescribing physicians to arrange alternative medications or lot replacements. Billing team should be prepared for potential medication changes that may affect drug dispensing claims and prior authorization requirements for alternative treatments.